Monday, August 15, 2016

The Red Tape Times (article 4)

Here is an illustration of the revolving door between the FDA and the Pharmaceutical industry

Robert Califf was a paid consultant for companies such as Eli Lilly, GlaxoSmithKline, and Merck before Obama nominated him to the position of FDA commissioner. And before being a paid consultant, he was the head of Duke's Clinical Trial Research Institute, which receives the majority of its funding from the pharmaceutical industry (according to its own annual report).

What could possibly go wrong by allowing former Pharma consultants and employees to run the FDA?

http://press.psprings.co.uk/bmj/february/rivaroxaban.pdf

13 of the 16 researchers listed on the ROCKET-AF trial study, used to get FDA approval for Xarelto, were either employees of Bayer, Janssen, or Johnson and Johnson, were consultants for these drug companies, or were on their advisory board. I think it's safe to say that the norm of reciprocity is stronger than people are willing to admit, and the solution of course isn't more regulation or de-regulation because whether you add more regulation or deregulate the same people will be in charge of the regulation, either through a regulatory body or a board of directors, in an inherently rigged system; the false dilemma (more regulation vs. deregulation) simply keeps people from seeing the true root of the problem. 

No comments:

Post a Comment